Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT00184613
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00184652
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 321
- Registration Number
- NCT00184561
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Tianjin, Tianjin, China
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 226
- Registration Number
- NCT00154414
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 177
- Registration Number
- NCT00154401
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 172
- Registration Number
- NCT00154427
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Use of NovoSeven® in Active Variceal Bleeding
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 265
- Registration Number
- NCT00154492
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 829
- Registration Number
- NCT00127283
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00127296
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT00124293
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Mississauga, Canada
© Copyright 2024. All Rights Reserved by MedPath